Dementia remains a formidable challenge for global healthcare, but scientists have identified a new molecular target that could reshape future therapies. Researchers at ETH Zurich in Switzerland have pinpointed the enzyme G protein-coupled receptor kinase 2 (GRK2) as a critical factor in Alzheimer's pathogenesis.
The team analyzed both mouse models and human brain tissue samples. They found that while normal GRK2 supports cellular health, a modified, inactive form of the enzyme accumulates abnormally in the brains of those with dementia. This dysfunctional GRK2 aggregates around mitochondria, the cell's powerhouses, blocking their pores and severely reducing energy supply.
This mitochondrial impairment creates a damaging feedback loop. Cellular stress triggers the production of more inactive GRK2, which further harms mitochondria and promotes the accumulation of amyloid-beta protein, a hallmark of Alzheimer's disease.
Leveraging this insight, the researchers developed a chemical agent named Compound 10. In laboratory tests on mice and human cells, the compound prevented abnormal GRK2 enzymes from clumping together. The result was improved mitochondrial function, reduced amyloid-beta accumulation, and preserved nerve cell functionality.
Compound 10 successfully slowed dementia progression in animal models and showed signs of broader anti-aging effects. While clinical application in humans requires further study, including larger-scale analysis of human tissue, the discovery offers a novel mechanism distinct from existing Alzheimer's drugs. Lead researcher Ursula Quitterer emphasizes that targeting GRK2 provides a new angle in the complex fight against neurodegeneration.